FOR IMMEDIATE RELEASE

                  Oragenics Breaks Ground for New Headquarters

ALACHUA, FL Feb. 18, 2004 - Oragenics, Inc. (OTC: OGEN; TSX-V:ORA.U), a publicly
held biotechnology  development  company,  will break ground today at 11:00 a.m.
for  a  new  headquarters  building  in  Progress  Corporate  Park  in  Alachua.
Oragenics,  currently  housed  in  the  University's  Sid  Martin  Biotechnology
Incubator, will be the first graduate of the Incubator to build in the park.

Oragenics has worked with architect  Paul Stresing and developer  Hawley-Wiggins
to design a 5300 sq. ft. facility with corporate  offices and R&D  laboratories,
which it will lease for five years.

Oragenics is an emerging  biotechnology  company  focused on the  development of
innovative  products and technologies for improving human health.  The company's
lead product is a novel oral rinse for the  prevention of tooth decay,  which is
anticipated to enter clinical  trials in 2004. The company is also  developing a
novel antibiotic with broad-spectrum activity against gram positive bacteria and
a probiotic product aimed at maintaining oral health. For more information about
Oragenics, please consult the company's website at www.oragenics.com.

Chuck Soponis,  President of Oragenics,  said,  "The move into a new home of our
own is another major step in the  development  and growth of Oragenics.  We will
leave the Sid Martin BDI with a great deal of gratitude  towards the  University
and the BDI  management  for  nurturing  our company  through  its early  growth
stages."

Located in  Alachua,  the 35,000  sq.  ft.  Sid Martin  Biotechnology  Incubator
provides  start-up  biotech  companies with support  essential for  accelerating
their launch into the  marketplace.  Business  development  support services and
assistance  with  access  to  seed  stage  venture  capital  are  combined  with
state-of-the-art  laboratories,  wet labs, greenhouse and animal facilities, and
common use  equipment  to support the  development  of young  biotech  companies
emerging from the fruits of University of Florida research.

Safe Harbor  Statement  Under the Private  Securities  Litigation  Reform Act of
1995: This release includes forward-looking  statements which reflect Oragenics'
current  views with respect to future events and  financial  performance.  These
forward-looking statements are based on management's beliefs and assumptions and
information currently available.  The words "believe",  "expect",  "anticipate",
"intend",  "estimate",  "project"  and similar  expressions  which do not relate
solely to historical  matters  identify  forward-looking  statements.  Investors
should be cautious in relying on  forward-looking  statements  because  they are
subject to a variety of risks, uncertainties, and other factors that could cause
actual  results  to  differ   materially   from  those  expressed  in  any  such
forward-looking  statements.  These factors include,  but are not limited to (1)
the  ability to  successfully  complete  development  and  commercialization  of
Oragenics'  Replacement Therapy for prevention of tooth decay, novel antibiotic,
and  probiotic  product for oral health;  (2) the ability to obtain  substantial
additional funding; (3) the ability to develop and commercialize products before
competitors;  and (4) other  factors  detailed from time to time in filings with
the Securities and Exchange Commission. We expressly disclaim any responsibility
to update forward-looking  statements. The TSX Venture Exchange has not reviewed
and does not accept  responsibility  for the  adequacy  or accuracy of this news
release.

                                      # # #
Contact:
Chuck Soponis
Oragenics, Inc.
386-418-4018